Highlights Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq Other stock markets 01:30:00 22/05/2024 am IST			5-day change	1st Jan Change
12.27 ^USD	+2.42%		+14.67%	+734.69%

11/04	Sector Update: Health Care Stocks Decline Thursday Afternoon	MT
11/04	Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Decline Thursday Afternoon	11/04	MT
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug	11/04	MT
Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation	11/04	DJ
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	09/04	CI
March Jobs Growth Exceed Expectations, Lifting US Equity Futures Pre-Bell	05/04	MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	05/04	MT
Jobs Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday	05/04	MT
Top Premarket Gainers	05/04	MT
Candel Therapeutics Shares Surge Premarket Following 'Positive' Phase 2 Results From Non-Metastatic Pancreatic Cancer Trial	05/04	MT
Top Midday Gainers	04/04	MT
Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer	04/04	CI
Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma	29/03	CI
Candel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate	06/03	CI
Candel Therapeutics Gets FDA Fast Track Label For Treatment of Recurrent High-Grade Glioma	14/02	MT
Candel Gets FDA Fast-Track Designation for CAN-3110 in Recurrent High-Grade Glioma	13/02	DJ
Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma	13/02	CI
Candel Therapeutics, Inc. Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer	12/12	CI
Candel Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Candel Therapeutics Presents Preclinical Data from Its Enlighten Discovery Platform At Sitc	06/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Highlights

Filters